FT. MYERS, Fla., March 1, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2015.
Fourth Quarter 2015 Highlights:
- 25% growth in base(1) test volume
- 12% reduction in Avg. Cost-per-test in base(1) business
- Record Adjusted EBITDA(2) of $2.9 million (even with $2.1 million of FISH reductions)
- Adjusted Diluted EPS(2) of $0.05 per share and Diluted EPS of ($0.03) per share
Full Year 2015 Highlights:
- 25% growth in base(1) test volume and 15% consolidated revenue growth
- 9% reduction in Avg. Cost per Test in base(1) business
- Record Adjusted EBITDA(2) of $9.7 million (even with $8.1 million of FISH reductions)
- Adjusted Diluted EPS(2) of $0.06 per share and Diluted EPS of ($0.04) per share
Consolidated Revenue for the fourth quarter was $27.2 million, an increase of 9% over the same period last year. Test volume growth in the base(1) business was 25% driven by increases in all major product lines and geographic regions. Average revenue-per-test decreased by 11.7%, primarily due to a significant reduction in reimbursement for Fluorescence in-situ Hybridization (“FISH”) testing as a result of changes in the FISH reimbursement structure that were introduced in 2015.
Average cost-of-goods-sold per test (“Cost per Test”) continued to fall in the fourth quarter, nearly offsetting the decreases in average-revenue-per test. Consolidated gross margin for the quarter was 44.8% as compared to 45.9% in last year’s fourth quarter.
Consolidated selling, general and administrative expenses (“SG&A”) increased by $7.3 million from the fourth quarter of last year. However $4.7 million of the increase were one-time costs related to completing the Clarient acquisition and $1.6 million was due to increases in variable stock-based compensation expense as a result of the 37% increase in the NeoGenomics stock price during the quarter.
Other income and expense for the quarter included $2.0 million of other income associated with amending our agreement with Covance. Fourth quarter net loss available to common stock was ($1.6 million), or ($0.03) per diluted share, versus a profit of $1.0 million, or $0.02 per diluted share, in the fourth quarter of last year.
Adjusted net income(2), after netting out certain one-time acquisition-related expenses, amortization of intangibles, deemed preferred stock dividends, and amortization of the preferred stock beneficial conversion feature, was $2.9 million in the fourth quarter versus $1.1 million in the prior year. Adjusted Diluted EPS(2) was $0.05 per share as compared to $0.02 per share in the prior year. Consolidated Adjusted EBITDA(2) for the quarter was $2.9 million, an increase of 6% versus the prior year, despite the $2.1 million impact caused by the FISH reimbursement reductions.
Douglas M. VanOort, the Company’s Chairman and CEO, commented, “Our acquisition of Clarient, completed on December 30th, has clearly transformed NeoGenomics into a much larger and stronger company. Integration activities are progressing well as we bring the best of each organization’s capabilities to our clients. We are pleased to report that the integration of the sales teams has already been completed, and we are receiving excellent response from our customers. As a result of strong business momentum and synergies, we expect 2016 revenue to more than double and Adjusted EBITDA to more than triple from 2015.”
Mr. VanOort continued, “We are also very pleased with our Quarter 4 results. Organic volume growth maintained the strong 25% pace set in Quarter 3 as we continue to gain market share. In addition, our 11.5% reduction Average Cost per Test allowed us to absorb most of the $2.1 million FISH reimbursement reductions with minimal impact to gross margin and to report a year-over-year increase in Adjusted EBITDA to a record $2.9 million.”
“Innovation continued to be an important focus area for us with 70 new or enhanced tests launched in 2015. Our targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, continue to gain acceptance by leading Pathologists and Clinicians throughout the country. Our Liquid Biopsy NeoLAB family of test offerings now includes 16 different liquid biopsy tests. In addition, Clarient’s expertise in PDL1 testing is being well received as an important new companion diagnostic. Our focus on innovation has broadened our cancer testing menu to be among the most comprehensive in the world and is fueling our growth.”
Mr. VanOort concluded, “We believe NeoGenomics is exceptionally well positioned as we move into 2016. Our core business is strong, we expect modest price-per-test improvement for the first time in six years, and we expect to gain substantial cost synergies and increased momentum as the year progresses. We are committed to remaining at the forefront of the ongoing revolution in cancer-related genetic and molecular testing and achieving our vision of becoming the world’s leading cancer testing and information company.”
Full-Year 2016 Financial Outlook:
NeoGenomics also issued preliminary guidance for fiscal year 2016 today. The Company expects full year 2016 revenue to be in the range of $240 - $250 million, Adjusted EBITDA(2) to be in the range of $33 - $38 million, Adjusted Net Income(2) to be in the range of $7 - $12 million, and Adjusted Diluted EPS to be in the range of $0.07 - $0.12 per share.
Investors and research analysts are advised that the Company expects that 2016 net income available to common stockholders calculated in accordance with GAAP will be impacted by certain non-cash charges, including (i) approximately $7.3 million of expense related to the amortization of customers lists and other intangibles from the Path Logic and Clarient acquisitions, (ii) approximately $7.4 million of deemed preferred stock dividends, and (iii) approximately $14.9 million of charges related to the amortization of the beneficial conversion feature related to the preferred stock issued in connection with the Clarient acquisition. These non-cash charges will be included in Diluted Earnings per Share, however should be removed from Adjusted Diluted Earnings per Share. As a result, Diluted Earnings per Share calculated in accordance with GAAP will likely be $0.35 - $0.40 per share lower than Adjusted Diluted Earnings per Share. We therefore recommend that analysts designate Adjusted Earnings per Share as the primary EPS when they report their estimates to Fact Set, First Call, or any other organizations that publish analyst consensus estimates.
The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
_____________________
(1) To facilitate year-over-year comparisons, base NeoGenomics figures exclude the impacts from the consolidation of the PathLogic and Clarient acquisitions.
(2) NeoGenomics has provided adjusted financial information that has not been prepared in accordance with GAAP, including “Adjusted EBITDA”, “Adjusted Net Income”, and “Adjusted EPS”. Adjusted EBITDA is defined as earnings before interest, taxes, depreciation, amortization, non-cash stock-based compensation expenses, and transaction related expenses and other non-recurring charges. Adjusted Net Income and Adjusted EPS exclude non-cash stock-based compensation expenses, transaction related expenses and other non-recurring changes, the deemed dividends on preferred stock, and the amortization of the beneficial conversion feature related to preferred stock issued in connection with the Clarient acquisition. See tables for reconciliation to GAAP net income.
Conference Call
The Company has scheduled a web-cast and conference call to discuss their fourth quarter 2015 and full year 2015 results on Tuesday, March 1, 2016 at 11:00 AM EST. Interested investors should dial (877) 407-0782 (domestic) and (201) 689-8567 (international) at least five minutes prior to the call and ask for Conference ID Number 13629440. A replay of the conference call will be available until 11:59 PM on March 15, 2016 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international). The playback conference ID Number is 13629440. The web-cast may be accessed under the Investor Relations section of our website at www.neogenomics.com or http://www.investorcalendar.com/IC/CEPage.asp?ID=174667. An archive of the web-cast will be available until 11:59 PM on June 1, 2016.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIAcertified clinical laboratory that specializes in cancer genetics diagnostic testing. The Company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.
Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Aliso Viejo, Irvine, Fresno and West Sacramento, CA; Tampa and Fort Myers, FL; Houston, TX and Nashville, TN. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.
Forward Looking Statements
Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including the information set forth in the “Full-Year 2016 Financial Outlook.” These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements as the result of the Company’s ability to continue gaining new customers, offer new types of tests, close and integrate its acquisition of the Clarient business, and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on March 3, 2015 as amended on April 30, 2015 and its subsequently filed Quarterly Reports on Form 10-Q. As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC.
To read full press release, please click here.
